NCT03383237Unknown2 期
Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Progression-free Survival (PFS)
研究概览
简要总结
The purpose of this study is to confirm the safety and efficacy of Apatinib as the Second-line Therapy in Malignant Melanoma.
详细描述
Melanoma is a malignant tumor caused by hyperplasia of abnormal melanoma cells.Most of the adults above 30 years of age occur in the skin, mucosa and internal organs. The investigators designed the study to explore the possibility of apatinib as the Second-line Therapy in Malignant Melanoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed the informed consent form prior to patient entry.
- •Pathologically confirmed first-line treatment of advanced malignant melanoma patients with at least one measurable lesion.
- •≥ 18 and ≤ 70 years of age.
- •Eastern Cooperative Oncology Group(ECOG) performance status 0 or
- •Life expectancy of more than 3 months.
- •Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥ 100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST ≤ 2.5×ULN (or ≤ 5×ULN in patients with liver metastases), Serum Cr ≤ 1.5×ULN, Cr clearance ≥ 60 mL/min;Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).
- •Female subjects of child-bearing potential must agree to use contraceptive measures starting 1 week before the administration of the first dose of apatinib until 6 months after discontinuing study drug. Male subjects must agree to use contraceptive measures during the study and 6 months after last dose of study drug.
排除标准
- •uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite optimal medical therapy), grade II The above myocardial ischemia or myocardial infarction, poor control of arrhythmia (including QTc interval male ≥ 450 ms, female ≥ 470 ms).
- •Patients previously treated with anticancer therapies also have a Toxicity Level> 1 in NCI CTCAE.
- •A variety of factors that affect oral absorption (such as inability to swallow, nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).
- •Patients with gastrointestinal bleeding risk may not be included, including the following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of melena and vomiting within 3 months; (3) ) For fecal occult blood (+) must be gastroscopy, clear whether the existence of gastrointestinal organic diseases.
- •Coagulation dysfunction (INR> 1.5, PT> ULN + 4s or APTT> 1.5 ULN), with bleeding tendency or ongoing thrombolysis or anti-blood coagulation treatment.
- •Long-term, unhealed wounds or fractures.
- •Active bleeding, within 30 days after major surgery.
- •Intracranial metastasis.
- •Pregnant or lactating women.
- •Cytotoxic drug treatment, radiotherapy within 3 weeks after treatment; had taken two or more targeted drugs, or into the group before the other three months have been taking other targeted drugs.
- •Other malignant tumors in the past 3 years.
- •The investigators believe there is any condition that may harm the subject or result in the subject's inability to meet or perform the research requirements.
- •Huge metastasis / recurrence (tumor diameter> 5 cm)。
- •Malignant pleural effusion or ascites, causing NCI CTCAE grading 2 or more people with dyspnea.
- •Any allergy to apatinib should be excluded.
- •Severe liver and kidney dysfunction (grade 4) patients should be excluded.
- •Persons with a history of substance abuse who can not be abdicated or have mental disorders.
- •According to the judgment of the researcher, there is a concomitant disease that seriously endangers the patient's safety or affects the patient in completing the study.
研究组 & 干预措施
Apatinib
Experimental
Apatinib 500mg/d,q.d.,p.o.
干预措施: Apatinib (Drug)
结局指标
主要结局
Progression-free Survival (PFS)
时间窗: up to 2 year
From date of randomization until the date of first documented progression or date of death from any cause
次要结局
- Objective Response Rate (ORR)(up to 1 year)
- Disease Control Rate (DCR)(up to 1 year)
- Overall survival(OS)(up to 2 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Apatinib as Second-line Treatment of Advanced Pancreatic CancerPancreatic NeoplasmsNCT02726854First Affiliated Hospital Xi'an Jiaotong University30
已完成
2 期
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic CholangiocarcinomaSecond-line TreatmentIntrahepatic CholangiocarcinomaNCT03251443Peking Union Medical College Hospital34
Unknown
1 期
A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma PatientsHepatocellular CarcinomaNCT02727309Peking University Cancer Hospital & Institute30
Unknown
2 期
Maintenance Treatment of Apatinib in Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT03130270Guilin Medical University, China29
Unknown
2 期
Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract CancersBiliary Tract CancerNCT03144856Sun Yat-sen University39